<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.biopharminternational.com/view/the-biopharm-brief-cosentyx-approved-in-polymyalgia-rheumatica-a-phase-3-survival-win-for-an-aml-vaccine-and-173-million-for-in-vivo-bone-marrow-editing</loc>
      <lastmod>2026-11-17T21:52:14.074Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:52:07.342Z</news:publication_date>
        <news:title><![CDATA[The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/marrow-therapeutics-173-million-series-a-b-bone-marrow-genetic-medicines</loc>
      <lastmod>2026-11-17T17:34:25.175Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T17:34:25.175Z</news:publication_date>
        <news:title><![CDATA[Marrow Therapeutics Raises $173 Million for In Vivo Blood Therapies]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/small-molecule-agility-informs-biologics-manufacturing-merck</loc>
      <lastmod>2026-11-17T17:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T17:00:00Z</news:publication_date>
        <news:title><![CDATA[Small-Molecule Agility Can Inform Biologics Manufacturing, Says Merck]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/commit-biologics-raises-60-million-to-take-complement-powered-immune-engager-com002-into-the-clinic</loc>
      <lastmod>2026-11-17T16:16:40.926Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T16:16:40.926Z</news:publication_date>
        <news:title><![CDATA[Commit Biologics Raises $60 Million to Take Complement-Powered Immune Engager COM002 Into the Clinic]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/fda-approves-cosentyx-as-first-anti-il-17-biologic-for-polymyalgia-rheumatica</loc>
      <lastmod>2026-11-17T14:40:40.658Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:40:40.658Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Cosentyx as First Anti-IL-17 Biologic for Polymyalgia Rheumatica]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/sellas-cancer-vaccine-galinpepimut-s-overall-survival-phase-3-regal-aml</loc>
      <lastmod>2026-11-17T14:37:14Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:37:14Z</news:publication_date>
        <news:title><![CDATA[SELLAS Cancer Vaccine Improves Overall Survival in Phase 3 AML Trial]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/one-injection-a-month-efimosfermin-takes-aim-at-cirrhosis-in-mash</loc>
      <lastmod>2026-11-17T14:11:51.042Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:11:51.042Z</news:publication_date>
        <news:title><![CDATA[One Injection a Month: Efimosfermin Takes Aim at Cirrhosis in MASH]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/examining-future-dna-enabled-therapies</loc>
      <lastmod>2026-11-17T11:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T11:00:00Z</news:publication_date>
        <news:title><![CDATA[Examining the Future of DNA-Enabled Therapies]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/the-hidden-cost-of-clinical-supply-unlocking-study-cash-flow-and-flexibility</loc>
      <lastmod>2026-11-17T05:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T05:00:00Z</news:publication_date>
        <news:title><![CDATA[The Hidden Cost of Clinical Supply: Unlocking Study Cash Flow and Flexibility]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/fda-s-rare-disease-framework-aims-for-consistency-across-review-divisions-says-former-fda-reviewer-paz-vellanki</loc>
      <lastmod>2026-11-16T19:17:44.582Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T19:17:44.582Z</news:publication_date>
        <news:title><![CDATA[FDA's Rare Disease Framework Aims for Consistency Across Review Divisions, Says Former FDA Reviewer Paz Vellanki]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/the-biopharm-brief-fda-rejects-ivonescimab-gazyva-becomes-the-first-approved-pmn-therapy-and-a-nanobody-approval-in-myasthenia-gravis</loc>
      <lastmod>2026-11-16T16:42:00.000Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T18:42:31.222Z</news:publication_date>
        <news:title><![CDATA[The BioPharm Brief: FDA Rejects Ivonescimab, Gazyva Becomes the First Approved pMN Therapy, and a Nanobody Approval in Myasthenia Gravis]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/fda-rejects-summit-s-pd-1-vegf-bispecific-ivonescimab-in-egfr-mutated-nsclc-citing-lack-of-survival-benefit</loc>
      <lastmod>2026-11-16T17:25:45.804Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T17:25:45.804Z</news:publication_date>
        <news:title><![CDATA[FDA Rejects Summit’s PD-1×VEGF Bispecific Ivonescimab in EGFR-Mutated NSCLC, Citing Lack of Survival Benefit]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/fda-approves-roche-obinutuzumab-gazyva-primary-membranous-nephropathy</loc>
      <lastmod>2026-11-16T17:06:34Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T17:06:34Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Roche's Obinutuzumab (Gazyva) for Membranous Nephropathy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/fda-approves-astrazeneca-gefurulimab-klygefa-generalized-myasthenia-gravis</loc>
      <lastmod>2026-11-16T16:53:35Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:53:35Z</news:publication_date>
        <news:title><![CDATA[FDA Approves AstraZeneca's Gefurulimab (Klygefa) for Generalized MG]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/deals-roundup-j-j-buys-ollin-lilly-adds-calytrix-and-novartis-and-sanofi-strike-platform-pacts</loc>
      <lastmod>2026-11-16T16:42:05.538Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:42:05.538Z</news:publication_date>
        <news:title><![CDATA[Deals Roundup: J&J Buys Ollin, Lilly Adds Calytrix, and Novartis and Sanofi Strike Platform Pacts]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/ron-lanton-report-ossium-healths-bone-marrow-bank</loc>
      <lastmod>2026-11-16T11:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T11:00:00Z</news:publication_date>
        <news:title><![CDATA[The Ron Lanton Report: Ossium Health's Bone Marrow Bank]]></news:title>
      </news:news>
	</url></urlset>